Contributions
Abstract: EP1636
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Introduction: Since 2009, three new oral medications have been approved in addition to the newly approved alemtuzumab and ocrelizumab. This has dramatically changed the treatment options for peole with multiple sclerosis (pwMS). These newer oral medications (OMs) allow patients to avoid injection-related side effects and improve the ease of medication administration.
Objectives: This retrospective study was conducted to examine the patient records of Dokuz Eylul MS Clinic.
Methods: The patient records (all clinic days throughout the year) in 2010, which OMs were not available, were compared to those in 2017. Patients who applied to the clinic for routine control, and having a clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), or primary progressive MS (PPMS) were included. Patients applied to the clinic for a suspected relapse were excluded.
Results: The records including 2045 visits in 2010 were compared to 2308 visits in 2017. No significant difference was found in age and disease duration of the patients visited in 2010 and 2017. There were significantly more number of patients with SPMS (26.8% vs. 20.2%, p< 0.001) in 2010; however, significantly less number of patients with RRMS (59.2% vs. 71.6%, p< 0.001). The number of patients with the Expanded Disability Status Scale (EDSS) scores of ≤3 were significantly higher in 2017 (73.7 vs.65.4%, p< 0.001). On the other hand, the number of patients with the EDSS scores of 6-6.5 and ≥7 were significantly less in 2017 (8.3% vs. 13.4% and 3.1 vs. 7.9%, respectively, p< 0.001). Significantly more patients with SPMS, EDSS scores of ≥7 (wheel-chair dependent patients) came to the clinic in 2010 compared to 2017 (2.7 vs. 1.4%, p< 0.001).
Conclusions: The increasing availability of new treatment options for patients with inadequate treatment response have changed the MS patient profile over the years. Especially OMs improved the patients adherance to the tratment. The proportion of patients with SPMS and higher EDSS scores reduced. Thus, the number of wheelchair-dependent patients also reduced.
Disclosure: Serkan Ozakbas: nothing to disclose
Bilge Piri Cinar: nothing to disclose
Yuksel Guven Yorgun: nothing to disclose
Turhan Kahraman: nothing to disclose
Abstract: EP1636
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Introduction: Since 2009, three new oral medications have been approved in addition to the newly approved alemtuzumab and ocrelizumab. This has dramatically changed the treatment options for peole with multiple sclerosis (pwMS). These newer oral medications (OMs) allow patients to avoid injection-related side effects and improve the ease of medication administration.
Objectives: This retrospective study was conducted to examine the patient records of Dokuz Eylul MS Clinic.
Methods: The patient records (all clinic days throughout the year) in 2010, which OMs were not available, were compared to those in 2017. Patients who applied to the clinic for routine control, and having a clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), or primary progressive MS (PPMS) were included. Patients applied to the clinic for a suspected relapse were excluded.
Results: The records including 2045 visits in 2010 were compared to 2308 visits in 2017. No significant difference was found in age and disease duration of the patients visited in 2010 and 2017. There were significantly more number of patients with SPMS (26.8% vs. 20.2%, p< 0.001) in 2010; however, significantly less number of patients with RRMS (59.2% vs. 71.6%, p< 0.001). The number of patients with the Expanded Disability Status Scale (EDSS) scores of ≤3 were significantly higher in 2017 (73.7 vs.65.4%, p< 0.001). On the other hand, the number of patients with the EDSS scores of 6-6.5 and ≥7 were significantly less in 2017 (8.3% vs. 13.4% and 3.1 vs. 7.9%, respectively, p< 0.001). Significantly more patients with SPMS, EDSS scores of ≥7 (wheel-chair dependent patients) came to the clinic in 2010 compared to 2017 (2.7 vs. 1.4%, p< 0.001).
Conclusions: The increasing availability of new treatment options for patients with inadequate treatment response have changed the MS patient profile over the years. Especially OMs improved the patients adherance to the tratment. The proportion of patients with SPMS and higher EDSS scores reduced. Thus, the number of wheelchair-dependent patients also reduced.
Disclosure: Serkan Ozakbas: nothing to disclose
Bilge Piri Cinar: nothing to disclose
Yuksel Guven Yorgun: nothing to disclose
Turhan Kahraman: nothing to disclose